The FDA has approved tirzepatide (Zepbound) as the first and only medication for obstructive sleep apnea (OSA) in adults with obesity. Clinical trials revealed that tirzepatide achieved an average ...

The US FDA has approved BRAFTOVI® (encorafenib) with cetuximab and mFOLFOX6 as a first-line therapy for BRAF V600E-mutant metastatic colorectal cancer. The Phase 3 BREAKWATER trial showed ...

We have honored to host Dr. Sara Naseri, CEO and Co-Founder of Qvin, a pioneering figure in women’s health innovation. In this session, we explore the groundbreaking Q-Pad technology, the first ...

The Phase 3 PATINA Trial shows that adding palbociclib (IBRANCE®) to standard maintenance therapy significantly extends progression-free survival (PFS) in HR+, HER2+ metastatic breast cancer.

AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering oral peptide IL23R inhibitor, currently in preclinical development for ...

The latest findings presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) reveal that patients with germline BRCA-mutated, HER2-negative breast cancer who received one year of the oral ...

Novartis announced that its drug Ribociclib (Kisqali®) combined with endocrine therapy (ET) demonstrates a sustained 28.5% reduction in distant recurrence for high-risk HR+/HER2- early breast cancer ...

General Inception, a global biotech company igniter, has acquired Enable Medicine, a leader in Artificial Intelligence-driven biological research, in a strategic equity partnership aimed at ...

The EMBER-3 trial showed that the new oral SERD, imlunestrant, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast cancer. In ESR1-mutated patients, it ...